Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Very-Low Risk Myelodysplastic Syndrome”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)Ended earlyNCT05568225
What this trial is testing

Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Who this might be right for
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Forma Therapeutics, Inc. 17
Not applicableNot Yet RecruitingNCT07752121
What this trial is testing

First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

Who this might be right for
Myelodysplastic Neoplasms
Bristol-Myers Squibb 190
Testing effectiveness (Phase 2)Ended earlyNCT02943668
What this trial is testing

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

Who this might be right for
AnemiaMyelodysplastic Syndrome
Fred Hutchinson Cancer Center 2
Large-scale testing (Phase 3)Not Yet RecruitingNCT07722988
What this trial is testing

Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes
Kyntra Bio 201
Testing effectiveness (Phase 2)Study completedNCT03900715
What this trial is testing

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Who this might be right for
Myelodysplastic Syndromes
Celgene 21
Large-scale testing (Phase 3)Active Not RecruitingNCT05949684
What this trial is testing

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

Who this might be right for
Myelodysplastic Syndromes
Bristol-Myers Squibb 402
Large-scale testing (Phase 3)Looking for participantsNCT07422480
What this trial is testing

Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Who this might be right for
Myelodysplastic SyndromeAnemia
Takeda 300
Testing effectiveness (Phase 2)Ended earlyNCT05178342
What this trial is testing

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Who this might be right for
Myelodysplastic SyndromesAnemia
University of Leipzig 38
Testing effectiveness (Phase 2)WithdrawnNCT07387354
What this trial is testing

Pacritinib With Aza for Upfront Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesMDSMyelodysplastic Syndrome, Unclassifiable+3 more
Thomas Jefferson University
Not applicableStudy completedNCT05520749
What this trial is testing

Efficacy and Safety of Luspatercept: a Study by Fondazione Italiana Sindromi Mielodisplastiche

Who this might be right for
Myeloid Dysplasia
Fondazione Italiana Sindromi Mielodisplastiche-ETS 215
Large-scale testing (Phase 3)Study completedNCT02631070
What this trial is testing

Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Celgene 229
Post-approval studies (Phase 4)Active Not RecruitingNCT05891249
What this trial is testing

Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

Who this might be right for
Anemia
Bristol-Myers Squibb 85
Testing effectiveness (Phase 2)Looking for participantsNCT04419649
What this trial is testing

Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesCytopenia
Takeda 160
Testing effectiveness (Phase 2)Looking for participantsNCT07319845
What this trial is testing

TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Takeda 42
Not applicableApproved For MarketingNCT05937568
What this trial is testing

Expanded Access for Treatment With Imetelstat

Who this might be right for
Myelodysplastic Syndromes
Geron Corporation
Large-scale testing (Phase 3)Looking for participantsNCT06499285
What this trial is testing

Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Who this might be right for
Myelodysplastic Syndromes
Takeda 225
Testing effectiveness (Phase 2)Active Not RecruitingNCT07052006
What this trial is testing

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

Who this might be right for
Myelodysplastic SyndromeAnemia in Myelodysplastic Syndromes
Halia Therapeutics, Inc. 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06594965
What this trial is testing

HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic SyndromesAnemiaMDS+1 more
Hansoh BioMedical R&D Company 176
Large-scale testing (Phase 3)Ended earlyNCT03263091
What this trial is testing

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Who this might be right for
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)Anemia
Kyntra Bio 184
Testing effectiveness (Phase 2)Ended earlyNCT05237713
What this trial is testing

Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

Who this might be right for
AnemiaMyelodysplastic Syndromes
University of Leipzig 10
Next Page